Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response
Patients with TRSRs demonstrated more prolonged survival and superior treatment responses to EV treatment. The role of TRSR as a surrogate marker of EV's efficacy should be further explored in prospective and sufficiently powered studies.
Authors
- Takuma Yuba
- Satoshi Inoue (ORCID: https://orcid.org/0000-0003-1247-3844)
- Tomohide Suzuki
- Yuri Yuguchi
- Koya Morishita
- Hiroki Sai (ORCID: https://orcid.org/0009-0008-2518-114X)
- Hirotaka Matsui (ORCID: https://orcid.org/0000-0002-6266-3227)
- Shusuke Akamatsu (ORCID: https://orcid.org/0000-0002-1394-7506)
- Akira Hayakawa (ORCID: https://orcid.org/0000-0003-2542-6617)
- Jun Nagayama (ORCID: https://orcid.org/0000-0001-6239-2917)
Institutions
- Kariya Toyota General Hospital (JP)
- Japanese Red Cross Nagoya Daiichi Hospital (JP)
- Toyohashi Municipal Hospital (JP)
- Komaki City Hospital (JP)
- Chukyo Hospital (JP)
- Yokkaichi Municipal Hospital (JP)
- Nagoya Medical Center (JP)
- Nagoya University (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1007/s10147-024-02672-3
- Citations
- 6
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.55
Funders
- Nagoya University